Roche scraps hoped-for cholesterol blockbuster

Back to TopCommentsE-mailPrintBookmark and Share

A second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies.

Swiss drugmaker Roche Holding AG said Monday it has halted testing of its dalcetrapib, which the company had hoped would become a blockbuster, with eventual annual sales of more than $1 billion. The drug was in expensive late-stage patient testing as a treatment to raise HDL, or so-called good cholesterol, in heart disease patients.

Basel-based Roche said it decided to pull the plug on the recommendation of its independent data and safety monitoring board after an interim analysis, in a study called dal-OUTCOMES, found no "clinically meaningful" benefit.

The best-known drug in that class, called CETP inhibitors, was Pfizer Inc.'s torcetrapib. It was scrapped five years ago due to safety problems. Merck & Co. and Indianapolis-based Eli Lilly and Co. both are developing drugs in the class. Merck's anacetrapib is in a huge late-stage study, and Lilly's evacetrapib will soon begin late-stage testing.

The CETP class once was seen as successors to the heavily advertised cholesterol-lowering statins taken by tens of millions of people to prevent plaque from building up in arteries and later triggering heart attacks and strokes. Those drugs, which collectively have racked up hundreds of billions of dollars in sales but mostly have generic competition now, include Lipitor and Crestor, plus the older drugs Zocor, Mevacor and Pravachol.

Testing of CETP inhibitors has been among the most expensive drug development programs even though not everyone was convinced they were a good bet, Bernstein Research analyst Dr. Tim Anderson noted Monday.

"Experts in the field of cholesterol management have remained uncertain about the general approach of raising HDL-cholesterol through CETP inhibition. Investors have also remained cautious," Anderson wrote to investors Monday.

Roche, the sixth-biggest drugmaker globally, said that two other late-stage studies of its dalcetrapib have been completed and three other studies were ongoing. Still, the company decided to terminate the drug's entire testing program.

"While we have always stated that dalcetrapib is a high-risk project, we are disappointed by the fact that this drug didn't provide benefit to the patients in our study," Dr. Hal Barron, Roche's chief medical officer and head of global product development, said in a statement, adding that Roche has a robust pipeline and is committed to developing new heart medicines.

Merck spokeswoman Pam Eisley said the company "remains confident in our development program for anacetrapib." A huge study called REVEAL that started last spring is enrolling 30,000 patients to see whether anacetrapib prevents heart attacks and strokes when added to a statin. Results aren't expected for several years. Another late-stage anacetrapib study already completed found it boosted good cholesterol by well over 100 percent and lowered bad cholesterol about 40 percent.

Merck pioneered the statin category with the first drug, Mevacor, and then followed up with Zocor, which was its top seller until generic competition hit in June 2006.

Meanwhile, Lilly said the company is committed to its evacetrapib and plans to start a late-stage study in the second half of this year. Spokeswoman Christina Gaines noted earlier testing showed evacetrapib raises good cholesterol up to 129 percent and reduces bad cholesterol by up to 36 percent, depending on dose.

Statins for years were among the most heavily prescribed drugs in developing countries, where heart disease is a top killer. Pfizer's Lipitor reigned as the top-selling drug in history for about eight years, with peak sales of $13 billion in 2006, but it got limited U.S. generic competition in December. By then, inexpensive generic versions of Zocor and the other older statins already had been nibbling at revenue for Lipitor, which will plunge when multiple generic versions hit drugstores on May 31.

Pfizer, the world's biggest drugmaker, had made it a priority to find a successor before the patent expired on Lipitor, which brought in about a quarter of its revenue from 2004 through 2009. But its heavily touted torcetrapib flamed out early in 2007, after roughly $800 million in testing, because it raised risk of heart attacks and strokes. That failure, along with a general decline in productivity from Pfizer's sprawling research labs, was widely seen as among the reasons the company spent $68 billion to buy fellow drugmaker Wyeth in 2009 and Pfizer's board forced out CEO Jeffrey Kindler in December 2010.

The pharmaceutical industry is challenged by "lagging R&D productivity and various ongoing/upcoming patent expirations on major drugs across the majority of drug companies," Anderson wrote.

He added that if all the CETP inhibitors and two closely watched drugs being developed to slow progression of Alzheimer's disease also fail, "investor patients could again be tested."


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. Angela IS the best RD

  2. We are a nation of speed. All of our younger lives are filled with deadlines, quotas and bottom lines. We start to ease out of the pressured rat-race when we finally see "retirement." The most enjoyable travel on the planet is passenger rail service. Indy to Chicago does not beat Megabus or Southwest Airlines in speed. Passenger rail however has the best seating, mammoth legroon, seat backs that recline to more than 45 degrees and employers that really want you to return as a customer. Indiana municipalities need to maintain subsidies to support this transportation mode. Losing it is loss for all of us.

  3. Good day! I just want to testify how i got my loan from Mr. Eric Lefkofsky after i applied several times from various loan lenders who claimed to also testify right in this forum,i thought the testimonies where real and i applied but they never gave me loan. I was in need of an urgent loan to start a business and i applied from various loan lenders who promised to help but they never gave me the loan. Until a friend of mine introduce me to this popular Mr. Eric Lefkofsky who promised to help me and indeed he did as he promised without any form of delay. I never thought there are still reliable loan lenders until i met Mr. Eric lefkofsky who indeed helped me with the loan and changed my belief. I promised to share this testimony after I got my loan. I don't know if you are in any way in need of a genuine and urgent loan,free feel to contact Mr. Eric Lefkofsky via their email{grouponfunding@hotmail.com}

  4. Its a THUG issue. Bleecker Street and NYX are thug bars. They attract thugs of all races. Places that attract thugs need to be kicked out of Broad Ripple. Ain't nobody got time for that!

  5. Hello everyone, My name is Marian Gareth, I am from the Texas, United State, am here to testify of how i got my loan from Mr Andre Frank {frankloancompany@yahoo.com} after i applied Two times from various loan lenders who claimed to be lenders right in this forum,i thought their lending where real and i applied but they never gave me loan. I was in need of an urgent loan to start a business and i applied from various loan lenders who promised to help but they never gave me the loan.Until a friend of mine introduce me to Mr Andre Frank the C.E.O of Andre Frank Loan Company who promised to help me with a loan of my desire and he really did as he promised without any form of delay, I never thought there are still reliable loan lenders until i met Mr Andre Frank, who really help me with my loan and changed my lief for better. I don't know if you are in need of an urgent loan, free feel to contact Mr Andre Frank on his email{ Frankloancompany@yahoo.com} for help